ACADIA PHARMACEUTICALS INC (ACAD) Stock News
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
ACAD Latest News, Press Relases and Analysis
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth investors.
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson’s disease. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN […]
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
Johnson & Johnson (NYSE:JNJ) is one of the best Dow stocks to invest in. Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support from hospitals that used reprocessed catheters. U.S. District […]
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent.
Mentions: JPM
Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: BPMC
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls
UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other Friday’s top performers. The stock market finished the trading week in the green territory as investors looked past the series of mixed corporate earnings […]
How much are home equity loan closing costs in 2025?
They’re less than mortgages’ upfront expenses, but they do add up.
UBS Upgrades Archer Daniels (ADM) Stock to Buy, Lifts PT
On May 19, UBS analyst Manav Gupta upped Archer-Daniels-Midland Company (NYSE:ADM)’s stock from “Neutral” to “Buy,” raising the price objective to $60 from the prior target of $55. The analyst highlighted the potential policy benefits, together with an optimistic outlook for its nutrition segment, as critical drivers. The House’s budget reconciliation bill has made it […]
GSK or ACAD: Which Is the Better Value Stock Right Now?
GSK vs. ACAD: Which Stock Is the Better Value Option?
Mentions: GSK
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
CoreWeave (CRWV) Stock Soars After Nvidia Discloses Stake
CoreWeave (NASDAQ:CRWV) shares surged 22% on May 16 and touched $80 after Nvidia Corp.’s (NASDAQ:NVDA) SEC filing (13G) revealed that it held around 24.2 million shares, or a 7% stake, as of March 31. Investors’ confidence in CoreWeave appears to have risen multi-fold after this disclosure, as the stake now is higher than the 5.2% […]
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nuplazid intellectual property protection while removing a perceived overhang on the shares. The court specifically concluded that Acadia demonstrated by preponderance of evidence that Aurobindo infringes patent claims, the analyst tells investors in a research no
Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital
BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperfo
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FENC
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FENC
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.